The molecular genetics of sulfonylurea receptors in the pathogenesis and treatment of insulin secretory disorders and type 2 diabetes

Current Diabetes Reports

Volumn 11, Issue 6, 2011, Pages 543-551

  Lang, Veronica ^a   Youssef, Nermeen ^a   Light, Peter E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Genetic variants; Insulin secretory disorder; K ATP channel; Monogenic mutations; Pharmacology; Sulfonylurea receptor; Type 2 diabetes

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; GLIBENCLAMIDE; GLICLAZIDE; GLINIDE DERIVATIVE; GLUCOSE; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.1; ORAL ANTIDIABETIC AGENT; SULFONAMIDE; SULFONYLUREA DERIVATIVE; SULFONYLUREA I 125; SULFONYLUREA RECEPTOR; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ABCC8 GENE; ABCC9 GENE; AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CELL FUNCTION; CELL METABOLISM; CONGESTIVE CARDIOMYOPATHY; DISEASE PREDISPOSITION; DRUG BINDING SITE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; DRUG TARGETING; ELECTRIC ACTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE; GENE DOSAGE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC RISK; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HUMAN; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN TREATMENT; ISOTOPE LABELING; KCNJ11 GENE; KCNJ8 GENE; MOLECULAR DIAGNOSIS; NEWBORN DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY; PHARMACOGENOMICS; POTASSIUM CHANNELOPATHY; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STIMULUS SECRETION COUPLING; TREATMENT PLANNING;

ATP-BINDING CASSETTE TRANSPORTERS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; KATP CHANNELS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RECEPTORS, DRUG;

EID: 80755132074     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-011-0233-8     Document Type: Review

References (75)

1. A Noma 1983 ATP-regulated K+channels in cardiac muscle Nature 305 5930 147 8 6310409 10.1038/305147a0 1:CAS:528:DyaL3sXltlOnurk%3D
2. FM Ashcroft DE Harrison SJH Ashcroft 1984 Glucose induces closure of single potassium channels in isolated rat pancreatic beta-cells Nature 312 5993 446 8 6095103 10.1038/312446a0 1:CAS:528:DyaL2MXit1Smtg%3D%3D (Pubitemid 15217837)
3. L Aguilar-Bryan, et al. 1995 Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion Science 268 5209 423 6 7716547 10.1126/science.7716547 1:CAS:528:DyaK2MXltFKktbw%3D
4. N Inagaki, et al. 1995 Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor Science 270 5239 1166 70 7502040 10.1126/science.270.5239.1166 1:CAS:528:DyaK2MXpsVykt7Y%3D
5. CG Nichols 2006 KATP channels as molecular sensors of cellular metabolism Nature 440 7083 470 6 16554807 10.1038/nature04711 1:CAS:528: DC%2BD28Xis1OlsLg%3D
6. FM Ashcroft FM Gribble 1999 ATP-sensitive K+channels and insulin secretion: their role in health and disease Diabetologia 42 8 903 19 10491749 10.1007/s001250051247 1:CAS:528:DyaK1MXkvF2ksLg%3D (Pubitemid 29369597)
7. JC Henquin 2000 Triggering and amplifying pathways of regulation of insulin secretion by glucose Diabetes 49 11 1751 60 11078440 10.2337/diabetes.49.11.1751 1:CAS:528:DC%2BD3cXnvVOmtr8%3D
8. L Aguilar-Bryan J Bryan 1999 Molecular biology of adenosine triphosphate-sensitive potassium channels Endocr Rev 20 2 101 35 10204114 10.1210/er.20.2.101 1:CAS:528:DyaK1MXisFygsro%3D (Pubitemid 29339588)
9. JP Clement, et al. 1997 Association and stoichiometry of K(ATP) channel subunits Neuron 18 5 827 38 9182806 10.1016/S0896-6273(00)80321-9 1:CAS:528:DyaK2sXjs1Omtr0%3D (Pubitemid 27232792)
10. FM Gribble F Reimann 2003 Sulphonylurea action revisited: the post-cloning era Diabetologia 46 7 875 91 12819907 10.1007/s00125-003-1143-3 1:STN:280:DC%2BD3szmtlSgsA%3D%3D (Pubitemid 36961311)
11. TP Flagg, et al. 2008 Differential structure of atrial and ventricular KATP: atrial KATP channels require SUR1 Circ Res 103 12 1458 65 18974387 10.1161/CIRCRESAHA.108.178186 1:CAS:528:DC%2BD1cXhsVWrtrjM
12. Schmid D, Stolzlechner M, Sorgner A, Bentele C, Assinger A, Chiba P, Moeslinger T. An abundant, truncated human sulfonylurea receptor 1 splice variant has prodiabetic properties and impairssulfonylurea action. Cellular and Molecular Life Sciences, 69(1). 2012.129-148.
13. ATP channel in the heart.
14. ATP channel activity can be regulated via ATP modulation of SNARE protein binding to the SUR1 subunit.
15. T Kikuta, et al. 2005 Docking and fusion of insulin secretory granules in SUR1 knock out mouse [beta]-cells observed by total internal reflection fluorescence microscopy FEBS Lett 579 7 1602 6 15757648 10.1016/j.febslet.2005. 01.074 1:CAS:528:DC%2BD2MXitFCiu7c%3D (Pubitemid 40341530)
16. CG Nichols, et al. 1996 Adenosine diphosphate as an intracellular regulator of insulin secretion Science 272 5269 1785 7 8650576 10.1126/science.272.5269.1785 1:CAS:528:DyaK28XjslWnu74%3D (Pubitemid 26256397)
17. A Terzic A Jahangir Y Kurachi 1995 Cardiac ATP-sensitive K+channels: regulation by intracellular nucleotoides and K+channel-opening drugs Am J Physiol 269 C525 45 7573382 1:CAS:528:DyaK2MXotlWrs7c%3D
18. H de Wet, et al. 2010 The ATPase activities of sulfonylurea receptor 2A and sulfonylurea receptor 2B are influenced by the C-terminal 42 amino acids FEBS J 277 12 2654 62 20553499 10.1111/j.1742-4658.2010.07675.x SUR isoforms possess different ATPase activities. This paper shows that the last 42 amino acids from NBD2 at the C-terminus of SUR2 are responsible for the different ATPase activities of SUR2A and SUR2A.
19. M Bienengraeber, et al. 2000 ATPase activity of the sulfonylurea receptor: a catalytic function for the KATP channel complex FASEB J 14 13 1943 52 11023978 10.1096/fj.00-0027com 1:CAS:528:DC%2BD3MXhtF2rsLg%3D
20. ATP channels and the disease states that result from aberrant expression or function of these proteins with a special focus on the pancreas and the cardiovascular system.
21. PE Light, et al. 2000 Molecular basis of protein kinase C-induced activation of ATP-sensitive potassium channels Proc Natl Acad Sci 97 16 9058 63 10908656 10.1073/pnas.160068997 1:CAS:528:DC%2BD3cXls12ksrw%3D (Pubitemid 30626673)
22. PE Light, et al. 2002 Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein Kinase A- and ADP-dependent mechanism Mol Endocrinol 16 9 2135 44 12198249 10.1210/me.2002-0084 1:CAS:528:DC%2BD38XmslCqs70%3D (Pubitemid 35013461)
23. PE Light, et al. 1996 Protein kinase C-induced changes in the stoichiometry of ATP binding activate cardiac ATP-sensitive K+channels: a possible mechanistic link to ischemic preconditioning Circ Res 79 3 399 406 8781473 1:CAS:528:DyaK28XlsVOgu70%3D (Pubitemid 26276900)
24. R Masia D Enkvetchakul CG Nichols 2005 Differential nucleotide regulation of KATP channels by SUR1 and SUR2A J Mol Cell Cardiol 39 3 491 501 15893323 10.1016/j.yjmcc.2005.03.009 1:CAS:528:DC%2BD2MXosVCrsLY%3D (Pubitemid 41133734)
25. MJ Riedel, et al. 2003 Kir6.2 polymorphisms sensitize beta-cell ATP-sensitive potassium channels to activation by acyl CoAs: a possible cellular mechanism for increased susceptibility to type 2 diabetes Diabetes 52 10 2630 5 14514649 10.2337/diabetes.52.10.2630 1:CAS:528:DC%2BD3sXotVWhsbY%3D (Pubitemid 37210554)
26. MJ Riedel PE Light 2005 Saturated and cis/trans unsaturated acyl CoA esters differentially regulate wild-type and polymorphic beta-cell ATP-sensitive K+channels Diabetes 54 7 2070 9 15983208 10.2337/diabetes.54.7.2070 1:CAS:528:DC%2BD2MXmtVelsbg%3D (Pubitemid 40911270)
27. GC Yaney BE Corkey 2003 Fatty acid metabolism and insulin secretion in pancreatic beta cells Diabetologia 46 10 1297 312 13680127 10.1007/s00125-003- 1207-4 1:CAS:528:DC%2BD3sXnvVCgurg%3D (Pubitemid 37297198)
28. J Duhault R Lavielle 1991 History and evolution of the concept of oral therapy in diabetes Diabetes Res Clin Pract 14 Suppl 2 S9 13 1794272 10.1016/0168-8227(91)90003-V
29. JM Feldman 1985 Glyburide: a second-generation sulfonylurea hypoglycemic agent. History, chemistry, metabolism, pharmacokinetics, clinical use and adverse effects Pharmacotherapy 5 2 43 62 3923453 1:CAS:528:DyaL2MXktlWrtr0%3D (Pubitemid 15103042)
30. G Trube P Rorsman T Ohno-Shosaku 1986 Opposite effects of tolbutamide and diazoxide on the ATP-dependent K+channel in mouse pancreatic beta-cells Pflügers Archiv-Eur J Physiol 407 5 493 9 10.1007/BF00657506 1:CAS:528:DyaL28XmtFyksrk%3D (Pubitemid 17175041)
31. NC Sturgess, et al. 1985 The sulphonylurea receptor may be an ATP-sensitive potassium channel Lancet 2 8453 474 5 2412077 10.1016/S0140- 6736(85)90403-9 1:CAS:528:DyaL2MXlvFeqsLk%3D
32. DA Nelson L Aguilar-Bryan J Bryan 1992 Specificity of photolabeling of beta-cell membrane proteins with an 125I-labeled glyburide analog J Biol Chem 267 21 14928 33 1634533 1:CAS:528:DyaK38XltVCjsbY%3D
33. WJ Malaisse 2003 Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus Treat Endocrinol 2 6 401 14 15981944 10.2165/00024677-200302060-00004 1:CAS:528:DC%2BD3sXhtVSjsbrL (Pubitemid 37462239)
34. JF Blickle 2006 Meglitinide analogues: a review of clinical data focused on recent trials Diabetes Metab 32 2 113 20 16735959 10.1016/S1262-3636(07) 70257-4 1:CAS:528:DC%2BD28XlsFGrtL8%3D
35. JF McLeod 2004 Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent Clin Pharmacokinet 43 2 97 120 14748619 10.2165/00003088-200443020-00003 1:CAS:528:DC%2BD2cXisFGku74%3D (Pubitemid 38283133)
36. CR Culy B Jarvis 2001 Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus Drugs 61 11 1625 60 11577798 10.2165/00003495- 200161110-00008 1:CAS:528:DC%2BD3MXnvVCqs70%3D (Pubitemid 32905281)
37. HM Phillippe KA Wargo 2010 Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus Ann Pharmacother 44 10 1615 23 20841518 10.1345/aph.1P136 This article reviews publications regarding the pharmacology, pharmacokinetics, efficacy, and safety of rapid-acting mitiglinide to determine its potential place in therapy for patients with T2D.
38. WH Vila-Carriles G Zhao J Bryan 2007 Defining a binding pocket for sulfonylureas in ATP-sensitive potassium channels FASEB J 21 1 18 25 17110465 10.1096/fj.06-6730hyp 1:CAS:528:DC%2BD2sXmvFeqtw%3D%3D (Pubitemid 46061354)
39. M Winkler, et al. 2007 Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A+B-site ligands J Pharmacol Exp Ther 322 2 701 8 17495126 10.1124/jpet.107.123224 1:CAS:528:DC%2BD2sXoslSjur8%3D (Pubitemid 47105784)
40. ATP channels that have been identified in PHHI, neonatal diabetes mellitus, atrial fibrillation, and dilated cardiomyopathy.
41. ATP channel activation mutations can be successfully switched to sulfonylurea therapy.
42. P Tammaro, et al. 2008 A Kir6.2 mutation causing severe functional effects in vitro produces neonatal diabetes without the expected neurological complications Diabetologia 51 5 802 10 18335204 10.1007/s00125-008-0923-1 1:CAS:528:DC%2BD1cXkt1yjsrY%3D
43. ATP channel inhibitors required high blood-brain barrier permeability.
44. S Reyes, et al. 2009 KATP channel Kir6.2 E23K variant overrepresented in human heart failure is associated with impaired exercise stress response Hum Genet 126 6 779 89 19685080 10.1007/s00439-009-0731-9 1:CAS:528: DC%2BD1MXhsVKgs7jF Blunted heart rate during exercise is a risk factor for mortality in patients with heart failure, and the common E23K polymorphism in the KCNJ11 gene is present in heart failure patients. This study establishes that patients with the homozygous KK genotype have an abnormal response to exercise as demonstrated by a blunted heart rate elevation during cardiorespiratory treadmill stress testing.
45. H de Wet, et al. 2007 Increased ATPase activity produced by mutations at arginine-1380 in nucleotide-binding domain 2 of ABCC8 causes neonatal diabetes Proc Natl Acad Sci 104 48 18988 92 18025464 10.1073/pnas.0707428104
46. AL Gloyn, et al. 2004 Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes N Engl J Med 350 18 1838 49 15115830 10.1056/NEJMoa032922 1:CAS:528: DC%2BD2cXjsVOhtbk%3D (Pubitemid 38917250)
47. AT Hattersley FM Ashcroft 2005 Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy Diabetes 54 9 2503 13 16123337 10.2337/diabetes.54.9.2503 1:CAS:528:DC%2BD2MXhtVSjs73P (Pubitemid 41233571)
48. AP Babenko, et al. 2006 Activating mutations in the ABCC8 gene in neonatal diabetes mellitus N Engl J Med 355 5 456 66 16885549 10.1056/NEJMoa055068 1:CAS:528:DC%2BD28Xnsl2ks70%3D (Pubitemid 44162273)
49. ER Pearson, et al. 2006 Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations N Engl J Med 355 5 467 77 16885550 10.1056/NEJMoa061759 1:CAS:528:DC%2BD28XnslyktrY%3D (Pubitemid 44162274)
50. W Mlynarski, et al. 2007 Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11 Nat Clin Pract Neurol 3 11 640 5 17982434 10.1038/ncpneuro0640 1:CAS:528:DC%2BD2sXht1CnsrzJ (Pubitemid 350048230)
51. JV Sagen, et al. 2004 Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy Diabetes 53 10 2713 8 15448106 10.2337/diabetes.53.10.2713 1:CAS:528:DC%2BD2cXotFymtLo%3D (Pubitemid 39299284)
52. MJ Riedel DC Steckley PE Light 2004 Current status of the E23K Kir6.2 polymorphism: implications for type-2 diabetes Hum Genet 116 3 133 45 15565284 10.1007/s00439-004-1216-5 (Pubitemid 40173997)
53. AL Gloyn, et al. 2003 Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes Diabetes 52 2 568 72 12540637 10.2337/diabetes.52.2.568 1:CAS:528:DC%2BD3sXhtFansbY%3D (Pubitemid 36173218)
54. O Alsmadi, et al. 2008 Genetic study of Saudi diabetes (GSSD): significant association of the KCNJ11 E23K polymorphism with type 2 diabetes Diabetes Metab Res Rev 24 2 137 40 17922473 10.1002/dmrr.777 1:CAS:528:DC%2BD1cXjtlemtr0%3D (Pubitemid 351284758)
55. ND Palmer, et al. 2008 Association of the Kir6.2 E23K variant with reduced acute insulin response in African-Americans J Clin Endocrinol Metab 93 12 4979 83 18796522 10.1210/jc.2008-0543 1:CAS:528:DC%2BD1cXhsVyqtbbN
56. Y Doi, et al. 2007 Impact of Kir6.2 E23K polymorphism on the development of type 2 diabetes in a general Japanese population: The Hisayama Study Diabetes 56 11 2829 33 17965318 10.2337/db06-1709 1:CAS:528:DC%2BD2sXhtlWitL3N (Pubitemid 350044927)
57. D Zhou, et al. 2009 The E23K variation in the KCNJ11 gene is associated with type 2 diabetes in Chinese and East Asian population J Hum Genet 54 7 433 5 19498446 10.1038/jhg.2009.54 1:CAS:528:DC%2BD1MXhtV2hsLrJ The common KCNJ11 E23K variant has been reported to be associated with T2D in various European-descent populations. This study confirms that the E23K variant is also associated with T2D susceptibility in East Asian populations.
58. JC Florez, et al. 2004 Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region Diabetes 53 5 1360 8 15111507 10.2337/diabetes.53.5.1360 1:CAS:528:DC%2BD2cXjslKhs78%3D (Pubitemid 38569024)
59. ATP channel that may contribute to the increased risk for T2D associated with the K23/A1369 risk haplotype. Moreover, the increased sensitivity of the K23/A1369 variant to the A-site sulfonylurea drug gliclazide (afforded by the ABCC8 A1369 risk allele) could provide a pharmacogenomic therapeutic approach for patients with T2D who are homozygous for both K23/A1369 risk alleles.
60. R Masia CG Nichols 2008 Functional clustering of mutations in the dimer interface of the nucleotide binding folds of the sulfonylurea receptor J Biol Chem 283 44 30322 9 18715873 10.1074/jbc.M804318200 1:CAS:528: DC%2BD1cXht1yntL%2FK
61. H Sakura, et al. 1996 Sequence variations in the human Kir6.2 gene, a subunit of the beta-cell ATP-sensitive K-channel: no association with NIDDM in while Caucasian subjects or evidence of abnormal function when expressed in vitro Diabetologia 39 10 1233 6 8897013 10.1007/BF02658512 1:CAS:528: DyaK28XmsVGqt7w%3D
62. 1c and consequently a lower risk for sulfonylurea-induced hypoglycemia.
63. G Sesti, et al. 2006 The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5′-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes J Clin Endocrinol Metab 91 6 2334 9 16595597 10.1210/jc.2005-2323 1:CAS:528:DC%2BD28XlvVCgtrc%3D (Pubitemid 43855025)
64. Y Feng, et al. 2008 Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients Diabetes Care 31 10 1939 44 18599530 10.2337/dc07-2248 1:CAS:528:DC%2BD1cXht1KksLfP
65. D Carling, et al. 2011 AMP-activated protein kinase: nature's energy sensor Nat Chem Biol 7 8 512 8 21769098 10.1038/nchembio.610 1:CAS:528:DC%2BC3MXovFyhsr0%3D This paper reviews the role of AMP-activated protein kinase (AMPK) as an energy sensor and considers the recent finding that ADP, as well as AMP, activates mammalian AMPK.
66. Y Lee, et al. 2011 Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice Diabetes 60 2 391 7 21270251 10.2337/db10-0426 1:CAS:528:DC%2BC3MXisVOmtb0%3D This study shows that blocking glucagon action, by genetic ablation of the glucagon receptor, prevents hypoglycemia in a mouse model of type 1 diabetes.
67. PE MacDonald, et al. 2007 A KATP channel-dependent pathway within α cells regulates glucagon release from both rodent and human islets of langerhans PLoS Biol 5 6 e143 17503968 10.1371/journal.pbio.0050143 (Pubitemid 46919946)
68. P Rorsman, et al. 2008 KATP-channels and glucose-regulated glucagon secretion Trends Endocrinol Metab 19 8 277 84 18771934 10.1016/j.tem.2008.07.003 1:CAS:528:DC%2BD1cXhtFCgurbP
69. RM Crawford, et al. 2002 Creatine kinase is physically associated with the cardiac ATP-sensitive k+channel in vivo FASEB J 16 1 102 4 11729098 1:CAS:528:DC%2BD38XlsF2rsg%3D%3D
70. P Krippeit-Drews, et al. 2003 Phosphocreatine as a determinant of K(ATP) channel activity in pancreatic beta-cells Pflügers Archiv Eur J Physiol 445 5 556 62 1:CAS:528:DC%2BD3sXjt1Ggu7k%3D (Pubitemid 36286889)
71. AJ Carrasco, et al. 2001 Adenylate kinase phosphotransfer communicates cellular energetic signals to ATP-sensitive potassium channels Proc Natl Acad Sci 98 13 7623 8 11390963 10.1073/pnas.121038198 1:CAS:528:DC%2BD3MXkslWlsLc%3D (Pubitemid 32567998)
72. ATP channel function in the heart and skeletal muscles raises overall body energy expenditure, and generates a lean phenotype resistant to high fat diet-induced obesity with compromised physical endurance.
73. ATP channel activity is regulated by AMPK-mediated phosphorylation of the Ser385 residue of the Kir6.2 subunit in pancreatic β cells.
74. ATP conductance, which may play a key role in inhibiting insulin secretion under low energy status.
75. JC Florez, et al. 2007 Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program Diabetes 56 2 531 6 17259403 10.2337/db06-0966 1:CAS:528:DC%2BD2sXhs1ajtrs%3D